Vivo Capital Fund X, L.P.

192 LYTTON AVENUE, PALO ALTO, CA, 94301 · (650) 688-0818

Pooled Investment Fund / Private Equity Fund · Limited Partnership· inc. DELAWARE true 2022

Fit score

—

Offering

—

Sold

$717.0M

% sold

—

Investors

Min investment

Exemption

506(b)

Filing history

Filed	Form	Rule	Offering	Sold	% sold	Investors
2026-01-20	D/A ·current	506(b)	—	$717.0M	—	20	EDGAR ↗

Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.

Frank Kung — Director, Palo Alto, CA
4 other raises
- Vivo Opportunity Fund, L.P. $816.9M of —
- Vivo Drakkar Co-Invest Fund, L.P. $0 of —
- Vivo Opportunity Co-Invest (Cycle 3), L.P. $0 of —
- Vivo Opportunity Cayman Fund, L.P. $148.5M of —
n/a Vivo Capital X, LLC — Promoter, Palo Alto, CA
Shan Fu — Director, Palo Alto, CA
4 other raises
- Vivo Opportunity Fund, L.P. $816.9M of —
- Vivo Drakkar Co-Invest Fund, L.P. $0 of —
- Vivo Opportunity Co-Invest (Cycle 3), L.P. $0 of —
- Vivo Opportunity Cayman Fund, L.P. $148.5M of —
Edgar Engleman — Director, Palo Alto, CA
1 other raise
- Vivo Drakkar Co-Invest Fund, L.P. $0 of —
Michael Chang — Director, Palo Alto, CA
3 other raises
- Vivo Drakkar Co-Invest Fund, L.P. $0 of —
- AEMS Corp. $100K of $700K · 14.3%
- SWNB BANCORP INC $30.0M of $30.0M · 100.0%
David Liu — Director, Palo Alto, CA
2 other raises
- Edesa Biotech, Inc. $3.5M of $3.5M · 100.0%
- Vivo Drakkar Co-Invest Fund, L.P. $0 of —
Gaurav Aggarwal — Director, Palo Alto, CA
5 other raises
- Vivo Opportunity Fund, L.P. $816.9M of —
- Vivo Drakkar Co-Invest Fund, L.P. $0 of —
- Bonum Therapeutics, Inc. $26.9M of $32.3M · 83.3%
- Vivo Opportunity Co-Invest (Cycle 3), L.P. $0 of —
- Vivo Opportunity Cayman Fund, L.P. $148.5M of —

Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.